share_log

B of A Securities Reinstates Neutral on Akero Therapeutics, Announces $30 Price Target

Moomoo 24/7 ·  Apr 22 06:21

B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment